Previous 10 | Next 10 |
home / stock / gnftf / gnftf news
Recently, Conatus Pharmaceuticals (CNAT) announced results for its phase 2b POLT-HCV-SVR study. What I must say about these results after having looked at them is that they were in the middle in terms of efficacy. The middle being that they weren't a complete failure or a complete success ov...
Noteworthy events during the week of April 8 - 14 for healthcare investors. More news on: Avita Medical Ltd., Immunovaccine Inc., Intercept Pharmaceuticals, Healthcare stocks news, , Read more ...
Editor's note: Seeking Alpha is proud to welcome Kailyn Hui as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Genfit ( GNFTF...
Recently, MediciNova ( MNOV ) announced that it had stopped its phase 2 NASH/NAFLD study early due too extremely positive efficacy achieved in an interim analysis. It met the primary endpoint of the study, and thus the company terminated the study early so that it can advance it immediat...
In a recent article, we discussed what makes Genfit’s ( OTCPK:GNFTF ) Elafibranor one of the most promising candidates in the NASH treatment development space. Given the unmet need (no approved therapies), Elafibranor’s mechanism of action and the potential it has shown in clinic...
Non-alcoholic fatty liver disease or NALFD is expected to become the next global epidemic (Sherif et al, 2015) . NAFLD is defined as accumulation of lipids inside the hepatocytes exceeding 5% of the weight of the liver and in the absence of liver disease etiologies such as chronic viral he...
Genfit ( OTCPK:GNFTF ): FY EPS of -€1.88 Revenue of €6.86M (+1.2% Y/Y) Press Release More news on: Genfit, Earnings news and commentary,
Cara Therapeutics (NASDAQ: CARA ) resumed with Buy rating and $22 (53% upside) price target at H.C. Wainwright. More news on: Cara Therapeutics Inc., Mirati Therapeutics, Inc., Fennec Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
In our previous article, we gave a brief introduction to the NASH space. We looked at the major players developing NASH therapies ( phase 2 and phase 3). We discussed the pathogenesis of NAFLD and NASH. Finally, we kicked off the series by looking at one of the leaders in the race to develop N...
Editor's note: Seeking Alpha is proud to welcome First Genesis Consulting as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Pro. Click here to find out more » A healt...
News, Short Squeeze, Breakout and More Instantly...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the positiv...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusi...
Ipsen’s Iqirvo ® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval GENFIT is eligible to ...